摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2-Cyclohexen-1-yl)oxyamine hydrochloride | 78730-62-8

中文名称
——
中文别名
——
英文名称
(2-Cyclohexen-1-yl)oxyamine hydrochloride
英文别名
O-cyclohex-2-en-1-ylhydroxylamine;hydrochloride
(2-Cyclohexen-1-yl)oxyamine hydrochloride化学式
CAS
78730-62-8
化学式
C6H11NO*ClH
mdl
——
分子量
149.62
InChiKey
SUBPKYZYLSCWJP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.41
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    35.2
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    (2-Cyclohexen-1-yl)oxyamine hydrochloride苯丙炔酸4-二甲氨基吡啶盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 3.0h, 以47%的产率得到N-(2-cyclohexen-1-yloxy)-3-phenylpropynamide
    参考文献:
    名称:
    金催化O-烯丙基异羟肟酸酯的顺序环化/重排反应:3-羟基异恶唑的原子经济合成
    摘要:
    已经开发了具有炔基部分的O-烯丙基异羟肟酸酯的金催化的顺序反应,用于制备3-羟基异恶唑和异恶唑-3-酮。值得注意的是,该涉及环化和重排的多米诺反应提供了以高度原子经济的方式容易地获得所需化合物的方法。
    DOI:
    10.1016/j.tetlet.2016.03.032
  • 作为产物:
    参考文献:
    名称:
    NOVEL VASCULAR LEAKAGEAGE INHIBITOR
    摘要:
    本公开涉及一种新型血管渗漏抑制剂。本发明的新型血管渗漏抑制剂抑制血管内皮细胞凋亡,抑制由VEGF诱导的肌动蛋白应激纤维的形成,并增强皮质肌动蛋白环结构,从而抑制血管渗漏。因此,本发明的血管渗漏抑制剂可以预防或治疗由血管渗漏引起的各种疾病。由于本发明的血管渗漏抑制剂是由商业可获得或易于合成的孕酮合成的,因此具有明显优越的商业合成可行性。
    公开号:
    US20140378399A1
点击查看最新优质反应信息

文献信息

  • Aminothiazole cycloalkenyloxyimino acetamido cephem derivatives
    申请人:Fujisawa Pharmaceutical Co., Ltd.
    公开号:US04394384A1
    公开(公告)日:1983-07-19
    The invention relates to new cephem compounds of high antimicrobial activity, the new cephem compounds comprising aminothiazole cycloalkenyloxyimino acetamido cephem derivatives.
    该发明涉及一种高抗微生物活性的新头孢菌素化合物,新的头孢菌素化合物包括氨基噻唑环烯氧基亚胺醋氨基头孢菌素衍生物。
  • Novel intermediates for preparing new cephem compounds
    申请人:Fujisawa Pharmaceutical Co., Ltd.
    公开号:US04529802A1
    公开(公告)日:1985-07-16
    This invention relates to novel cephem compounds, of high antimicrobial activity, and to novel compounds which are useful as intermediates therefor, of the formula: ##STR1## wherein R.sup.1 is amino or a protected amino group; and R.sup.2 is cyclo (lower) alkenyl, or salt thereof.
    本发明涉及一种新的头孢菌素化合物,具有高度的抗微生物活性,以及用作其中间体的新化合物,其化学式为:##STR1## 其中R.sup.1是氨基或保护氨基基团;R.sup.2是环状(较低)烯基,或其盐。
  • Cephem compounds, processes for their preparation and pharmaceutical compositions containing them
    申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
    公开号:EP0025199A2
    公开(公告)日:1981-03-18
    Cephem compounds of the formula: wherein R1 is amino or a a protected amino group; R2 is cyclo(lower)alkenyl; R3 is carboxy or a protected carboxy group; R'is hydrogen or a group of the formula: -CH2-R4a [wherein R4a is acyloxy, amino (lower) alkylthio, a protected amino(lower) alkylthio group, pyridinium which may have suitable substituent(s) or a heterocyclicthio group which may have suitable substituent(s)], and R5 is hydrogen or lower alkyl, with proviso that R is COO- when R4a is pyridinium which may have suitable substituent(s), and pharmaceutically acceptable salts thereof and process for their preparation, and also a pharmaceutical composition comprising, as an effective ingredient, the above compound in association with a pharmaceutically acceptable, substantially nontoxic carrier or excipient. The invention also relates to the starting compounds and their preparation.
    式中的 Cephem 化合物: 其中 R1 是氨基或受保护的氨基; R2 是环(低级)烯基 R3 是羧基或受保护的羧基; R'是氢或一个式中的基团:-CH2-R4a [其中 R4a 是酰氧基、氨基(低级)烷硫基、受保护的氨基(低级)烷硫基、可有适当取代基的吡啶鎓或可有适当取代基的杂环鎓基团],R5 是氢或低级烷基,但当 R4a 是可有适当取代基的吡啶鎓时,R 是 COO-、和其药学上可接受的盐及其制备工艺,以及一种药物组合物,其有效成分包括上述化合物与药学上可接受的、基本上无毒的载体或赋形剂。本发明还涉及起始化合物 及其制备方法。
  • Glucal-conjugated sterols as novel vascular leakage blocker: Structure–activity relationship focusing on the C17-side chain
    作者:Kyeojin Kim、Sony Maharjan、Changjin Lim、Nam-Jung Kim、Vijayendra Agrawal、Young Taek Han、Sujin Lee、Hongchan An、Hwayoung Yun、Hyun-Jung Choi、Young-Guen Kwon、Young-Ger Suh
    DOI:10.1016/j.ejmech.2014.01.027
    日期:2014.3
    A series of glucal-conjugated sterols as novel vascular leakage blocker were identified through design, synthesis and biologically evaluation. In addition, the structure-activity relationship (SAR) of the glucal-conjugated sterols focusing on the C-17-side chain was also established. The sterol analogs linked with the rigid C-17-side chain side chains exhibited potent cell survival activities. In particular, analog 211, which possesses a cyclopentyl oxime moiety, was shown to have excellent pharmacological effects on retinal vascular leakage in a diabetic mouse model. (C) 2014 Elsevier Masson SAS. All rights reserved.
  • New starting compounds for preparing cephem compounds and processes for their preparation
    申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
    公开号:EP0088454B1
    公开(公告)日:1986-03-05
查看更多